In a study with an anti-PD-1 antibody in melanoma patients, the infiltration of CD8+ T cells was higher both at the invasive tumor margin and in the tumor parenchyma in the pre-treatment samples of responders compared to nonresponders [45]. The gene discussed is CD8A; the disease is neoplasm.